U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS
Bivalirudin is a synthetic 20 amino acid peptide rationally designed based on structural studies of hirudin, a naturally occurring anticoagulant. Bivalirudin is sold under the brand name Angiomax and is indicated for use as an anticoagulant in patients with unstable angina undergoing percutaneous transluminal coronary angioplasty (PTCA). It is intended for use with aspirin and has been studied only in patients receiving concomitant aspirin. Bivalirudin directly inhibits thrombin by binding simultaneously to its active catalytic site and its substrate recognition site.

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
Target ID: P00734|||Q9UCA1
Gene ID: 2147.0
Gene Symbol: F2
Target Organism: Homo sapiens (Human)
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Palliative
ANGIOMAX

Approved Use

Angiomax™ is indicated for use as an anticoagulant in patients with unstable angina undergoing percutaneous transluminal coronary angioplasty (PTCA). Angiomax is intended for use with aspirin and has been studied only in patients receiving concomitant aspirin.

Launch Date

9.7683839E11
PubMed

PubMed

TitleDatePubMed
Thrombin-specific inhibition by and slow cleavage of hirulog-1.
1992 May 1
The use of bivalirudin in patients with renal impairment.
2000 Dec
Hirulog-1 reduces expression of platelet-derived growth factor in neointima of rat carotid artery induced by balloon catheter injury.
2000 Mar-Apr
[Direct thrombin antagonists].
2001 Apr
Bivalirudin (Angiomax) for angioplasty.
2001 Apr 30
New anticoagulants.
2001 Aug
A second look at bivalirudin.
2001 Dec
Direct and indirect antithrombins. Heparins, low molecular weight heparins, heparinoids, and hirudin.
2001 Feb
From the Food and Drug Administration.
2001 Feb 14
Ecarin clotting time is sensitive to heparinoids: comparison of two different techniques.
2001 Jan
Thrombin inhibitor approved for anticoagulation during angioplasty.
2001 Mar 1
Bivalirudin: a new approach to anticoagulation.
2001 Mar-Apr
Hirulog-like peptide reduces balloon catheter injury induced neointima formation in rat carotid artery without increase in bleeding tendency.
2001 Mar-Apr
Laser-induced noninvasive vascular injury models in mice generate platelet- and coagulation-dependent thrombi.
2001 May
Advances in the development of thrombin inhibitors.
2001 May
Caspofungin acetate, bivalirudin.
2001 Oct 1
Bivalirudin for percutaneous coronary intervention and in acute coronary syndromes.
2001 Sep
Direct thrombin inhibitors for percutaneous coronary intervention in the current era of platelet glycoprotein IIb/IIIa inhibition.
2002 Apr
Bivalirudin, a bivalent, thrombin specific anticoagulant as an alternative to heparin in interventional procedures as an alternative to heparin in interventional procedures.
2002 Aug
Bivalirudin: a direct thrombin inhibitor for percutaneous transluminal coronary angioplasty.
2002 Aug
Direct thrombin inhibitors in acute coronary syndromes.
2002 Aug 10
Current anticoagulation options in percutaneous intervention: designing patient-specific strategies.
2002 Fall
Direct thrombin inhibitors in acute coronary syndromes: principal results of a meta-analysis based on individual patients' data.
2002 Jan 26
Direct thrombin inhibitors.
2002 Jul
Decreased platelet reactivity in blood anticoagulated with bivalirudin or enoxaparin compared with unfractionated heparin: implications for coronary intervention.
2002 Jun
Bivalirudin pharmacokinetics and pharmacodynamics: effect of renal function, dose, and gender.
2002 Jun
Selective inhibition of coagulation factors: advances in antithrombotic therapy.
2002 Jun
A practical cost analysis of bivalirudin.
2002 Jun
Bivalirudin administration during percutaneous coronary intervention: emphasis on high-risk patients.
2002 Jun
Clinical pharmacology of bivalirudin.
2002 Jun
Bivalirudin with planned or provisional abciximab versus low-dose heparin and abciximab during percutaneous coronary revascularization: results of the Comparison of Abciximab Complications with Hirulog for Ischemic Events Trial (CACHET).
2002 May
Gateways to clinical trials.
2002 Oct
Heparin-induced thrombocytopenia: pathophysiology and new treatment options.
2002 Sep-Dec
Management of thrombotic and cardiovascular disorders in the new millenium.
2003 Apr
Clinician update: direct thrombin inhibitors in acute coronary syndromes.
2003 Feb
Alternative methods of anticoagulation for dialysis-dependent patients with heparin-induced thrombocytopenia.
2003 Jan-Feb
Bivalirudin in peripheral vascular interventions: a single center experience.
2003 Jul
Economic impact of bleeding complications and the role of antithrombotic therapies in percutaneous coronary intervention.
2003 Jul 15
Predicting the pharmacology of thrombin inhibitors.
2003 May
An assessment of different filter systems for extracorporeal elimination of bivalirudin: an in vitro study.
2003 May
Comparison of effectiveness and safety of three different antithrombotic regimens (bivalirudin, eptifibatide, and heparin) in preventing myocardial ischemia during percutaneous coronary intervention.
2003 Nov 1
Patents

Sample Use Guides

The recommended dosage of Angiomax (bivalirudin) is an intravenous (IV) bolus dose of 1.0 mg/kg followed by a 4-hour IV infusion at a rate of 2.5 mg/kg/h. After completion of the initial 4-hour infusion, an additional IV infusion of Angiomax may be initiated at a rate of 0.2 mg/kg/h for up to 20 hours if needed.
Route of Administration: Intravenous
Name Type Language
BIVALIRUDIN
EMA EPAR   INN   MART.   MI   USAN   VANDF   WHO-DD  
INN   USAN  
Official Name English
BIVALIRUDIN [INN]
Common Name English
BIVALIRUDIN [WHO-DD]
Common Name English
BIVALIRUDIN [ORANGE BOOK]
Common Name English
BIVALIRUDIN [VANDF]
Common Name English
BIVALIRUDIN [MART.]
Common Name English
BIVALIRUDIN [EMA EPAR]
Common Name English
BG-8967
Code English
L-LEUCINE, D-PHENYLALANYL-L-PROLYL-L-ARGINYL-L-PROLYLGLYCYLGLYCYLGLYCYLGLYCYL-L-ASPARAGINYLGLYCYL-L-.ALPHA.-ASPARTYL-L-PHENYLALANYL-L-.ALPHA.-GLUTAMYL-L-.ALPHA.-GLUTAMYL-L-ISOLEUCYL-L-PROLYL-L-.ALPHA.-GLUTAMYL-L-.ALPHA.-GLUTAMYL-L-TYROSYL-
Systematic Name English
BIVALIRUDIN [MI]
Common Name English
BIVALIRUDIN [USP-RS]
Common Name English
BG8967
Code English
BIVALIRUDIN [USAN]
Common Name English
Classification Tree Code System Code
WHO-ATC B01AE06
Created by admin on Sat Jun 26 17:00:43 UTC 2021 , Edited by admin on Sat Jun 26 17:00:43 UTC 2021
FDA ORPHAN DRUG 200204
Created by admin on Sat Jun 26 17:00:43 UTC 2021 , Edited by admin on Sat Jun 26 17:00:43 UTC 2021
NDF-RT N0000175980
Created by admin on Sat Jun 26 17:00:43 UTC 2021 , Edited by admin on Sat Jun 26 17:00:43 UTC 2021
NDF-RT N0000175518
Created by admin on Sat Jun 26 17:00:43 UTC 2021 , Edited by admin on Sat Jun 26 17:00:43 UTC 2021
NCI_THESAURUS C263
Created by admin on Sat Jun 26 17:00:43 UTC 2021 , Edited by admin on Sat Jun 26 17:00:43 UTC 2021
Code System Code Type Description
EVMPD
SUB05862MIG
Created by admin on Sat Jun 26 17:00:43 UTC 2021 , Edited by admin on Sat Jun 26 17:00:43 UTC 2021
PRIMARY
DRUG CENTRAL
385
Created by admin on Sat Jun 26 17:00:43 UTC 2021 , Edited by admin on Sat Jun 26 17:00:43 UTC 2021
PRIMARY
MERCK INDEX
M2581
Created by admin on Sat Jun 26 17:00:43 UTC 2021 , Edited by admin on Sat Jun 26 17:00:43 UTC 2021
PRIMARY
DRUG BANK
DB00006
Created by admin on Sat Jun 26 17:00:43 UTC 2021 , Edited by admin on Sat Jun 26 17:00:43 UTC 2021
PRIMARY
CAS
128270-60-0
Created by admin on Sat Jun 26 17:00:43 UTC 2021 , Edited by admin on Sat Jun 26 17:00:43 UTC 2021
PRIMARY
NCI_THESAURUS
C47415
Created by admin on Sat Jun 26 17:00:43 UTC 2021 , Edited by admin on Sat Jun 26 17:00:43 UTC 2021
PRIMARY
FDA UNII
TN9BEX005G
Created by admin on Sat Jun 26 17:00:43 UTC 2021 , Edited by admin on Sat Jun 26 17:00:43 UTC 2021
PRIMARY
WIKIPEDIA
Bivalirudin
Created by admin on Sat Jun 26 17:00:43 UTC 2021 , Edited by admin on Sat Jun 26 17:00:43 UTC 2021
PRIMARY
EPA CompTox
128270-60-0
Created by admin on Sat Jun 26 17:00:43 UTC 2021 , Edited by admin on Sat Jun 26 17:00:43 UTC 2021
PRIMARY
USP_CATALOG
1076013
Created by admin on Sat Jun 26 17:00:43 UTC 2021 , Edited by admin on Sat Jun 26 17:00:43 UTC 2021
PRIMARY USP-RS
INN
7282
Created by admin on Sat Jun 26 17:00:43 UTC 2021 , Edited by admin on Sat Jun 26 17:00:43 UTC 2021
PRIMARY
LACTMED
Bivalirudin
Created by admin on Sat Jun 26 17:00:43 UTC 2021 , Edited by admin on Sat Jun 26 17:00:43 UTC 2021
PRIMARY
RXCUI
60819
Created by admin on Sat Jun 26 17:00:43 UTC 2021 , Edited by admin on Sat Jun 26 17:00:43 UTC 2021
PRIMARY